[quick news] on November 29, 2018, "broad spectrum" anticancer drug vitrakvi is not a "magic drug"

"Broad spectrum" anticancer drug vitrakvi is not a "magic drug" vitrakvi, also known as larotrectinib It is a precision anticancer drug jointly developed by Bayer and Loxo oncology It was approved by the US FDA on November 26 and listed on the market It is the first "broad spectrum" anticancer drug unrelated to tumor type It is understood that vitrakvi is an oral Trk inhibitor, which has therapeutic effect on advanced solid tumor patients whose tumors cannot be removed or have already metastasized It is suitable for lung cancer, thyroid cancer, melanoma, stomach cancer, colon cancer, etc Trk is an important signal pathway regulating cell communication and tumor growth Ntrk is the gene encoding Trk Many tumors carry ntrk gene fusion mutations, so vitrakvi can be used across a variety of tumor types, that is, it has "broad spectrum" characteristics But vitrakvi is not as "magical" as some reports say According to reports, before using the new anticancer drug, cancer patients need to do gene testing to check whether they carry ntrk gene fusion mutation to determine whether the drug is suitable for their own diseases If it is determined to be suitable, a better therapeutic effect can be achieved Http://news.scienceet.cn/htmlnews/2018/11/420507.shtm the second phase clinical trial of new antibiotic mrx-4 was launched in the United States to start the second phase clinical trial of new antibiotic contezolid acefosamil (also known as mrx-4) developed by biopharmaceutical company mengke Pharmaceutical Co., Ltd in the United States This new drug will be used to treat the first patients in the United States, including MRSA and VRE Acute skin and skin tissue infections caused by Gram-positive bacteria inside Mrx-4 is a prodrug of oral antibiotic C ontezolid (mrx-i), which is carrying out a three-stage clinical study on the treatment of complex skin and soft tissue infections in China Acute skin and tissue infections are very common in clinical practice In the United States alone, there are about 10 million outpatients and almost 1 million inpatients in one year This phase II clinical trial program recruited up to 200 patients in seven clinical centers across the United States to evaluate the efficacy and safety of mrx-4 oral and injectable preparations for 10-14 days of treatment The test is expected to be completed by mid-2019 Http://digitalpaper.stdaily.com/http_ / 29 / content_ HTM? Div = - 1 Costa launched the coffee cup that can "brush cup payment" Costa, the largest coffee chain in the UK, launched the coffee cup with NFC payment chip inside Customers can recharge the chip and then buy coffee through "brush cup payment" The chip can be used not only in Costa stores, but also in any place that supports NFC payment NFC paid coffee cups are designed to encourage people to reduce the use of disposable paper coffee cups, because only 1% of disposable paper coffee cups will be recycled Https:// electronic gloves enable the robot to have the sense of touch Engineers from Stanford University have invented a high-tech glove This electronic glove mimics the way human skin works There is an electronic sensor on the fingertip of the glove, similar to the biological sensor in human skin Each sensor consists of three layers of flexible materials, which can measure the strength and direction of pressure simultaneously The researchers say the technology to control sensors is still being perfected, but their invention can significantly improve the flexibility of robots This technology can be applied to robot assisted high-precision surgery in the future Https:// the trademark online service system went online in an all-round way and the State Intellectual Property Office held the launching ceremony of the trademark online service system on 27th, which is a breakthrough change in the trademark service carrier and service mode At present, the goal of trademark reform within the year of "substantially shortening the review cycle" has been completed in advance The average review cycle of trademark registration has been shortened to 5 months and 28 days, and the goal of shortening the average review cycle of trademark registration to less than 6 months has been achieved in advance Shen Changyu, director of the State Intellectual Property Office, said that he will firmly grasp the general basis of seeking progress in stability and the requirements of high-quality development, adhere to the priority of quality first and efficiency, and constantly improve system construction, business management and information construction http://paper.people.com.cn/rmrb/html/2018-11/28/nw.D110000renmrb_20181128_5-02.htm